Home › Trials › NCT05599191

Evaluating BLU-5937 for treating persistent cough in adults

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough

Phase 3 Interventional Bellus Health Inc. - a GSK company · NCT05599191

This study is testing a new medication called BLU-5937 to see if it can help adults with a long-lasting cough feel better over 12 weeks.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment825 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorBellus Health Inc. - a GSK company Industry-sponsored
Locations183 sites (Jasper, Alabama and 182 other locations)
Trial IDNCT05599191 on ClinicalTrials.gov

What this trial studies

This Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study aimed at assessing the efficacy and safety of BLU-5937 in adults suffering from refractory chronic cough (RCC). Participants will be monitored for changes in their 24-hour cough frequency over a 12-week period. The study includes a parallel-arm design, where one group receives the active treatment and another receives a placebo. The trial seeks to provide insights into the potential benefits of BLU-5937 for individuals with this challenging condition.

Who should consider this trial

Good fit: Ideal candidates are adults with refractory chronic cough lasting at least one year who can provide informed consent.

Not a fit: Patients with chronic obstructive pulmonary disease (COPD), bronchiectasis, or other significant respiratory conditions will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce cough frequency and improve the quality of life for patients with refractory chronic cough.

How similar studies have performed: Previous studies have shown promise in treating chronic cough with similar approaches, but this specific treatment is being evaluated for the first time in this context.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Capable of giving signed informed consent
* Refractory chronic cough (including unexplained chronic cough) for at least one year
* Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

Exclusion Criteria:

* Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma
* Respiratory tract infection within 4 weeks before screening
* Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
* History of malignancy in the last 5 years
* History of alcohol or drug abuse within the last 3 years
* Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
* Previous participation in a BLU-5937 trial

Where this trial is running

Jasper, Alabama and 182 other locations

+133 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Refractory Chronic Cough
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.